New framework agreement focuses on a loan repayment plan, allowing the pharmaceutical firm to refocus on its core CNS pipeline.
The unsolicited offer represents a 53% premium, as Mobix escalates its takeover attempt for the semiconductor firm.
The merger signals accelerating consolidation within the U.S. regional banking sector, creating the nation's 9th largest bank.
Deal with Deriva Energy expected to be immediately accretive, boosting renewable energy assets and targeting a cash available for distribution (CAFD) yield over 12%.
The deal will see the Singapore-based social technology company list on the Nasdaq, valuing the combined entity at approximately $300 million.
The marketing application for AVT23, a biosimilar to the multi-billion dollar asthma drug Xolair, marks a key regulatory step for Alvotech in the European market.
First patients implanted with the novel neurostimulator marks a key step in challenging market leader Inspire Medical after recent FDA approval.
The designation for ALTO-101 targets cognitive impairment, a debilitating condition with no currently approved treatments, signaling a major regulatory milestone.